Enovis Corporation (ENOV) Stock Competitors & Peer Comparison
See (ENOV) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ENOV | $22.02 | -3.04% | 1.3B | 6.51 | $3.38 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $92.71 | -1.50% | 161.5B | 17.79 | $5.21 | +2.62% |
| ISRG | $405.97 | +0.31% | 143.8B | 42.20 | $9.62 | N/A |
| SYK | $330.52 | -0.66% | 126.6B | 24.66 | $13.39 | +1.03% |
| MDT | $80.93 | -0.06% | 103.6B | 14.63 | $5.53 | +3.52% |
| BSX | $43.48 | -1.70% | 64.6B | 14.02 | $3.10 | N/A |
| EW | $91.18 | +0.44% | 52.5B | 33.77 | $2.70 | N/A |
| RMD | $198.43 | -0.93% | 28.8B | 18.42 | $10.77 | +1.21% |
| DXCM | $69.98 | -0.23% | 27B | 30.03 | $2.33 | N/A |
Stock Comparison
ENOV vs BSX-PA Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ENOV is priced at $22.02, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ENOV's ROE is -0.60%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, ENOV is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check BSX-PA's competition here
ENOV vs ABT Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, ABT has a market cap of 161.5B. Regarding current trading prices, ENOV is priced at $22.02, while ABT trades at $92.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas ABT's P/E ratio is 17.79. In terms of profitability, ENOV's ROE is -0.60%, compared to ABT's ROE of +0.12%. Regarding short-term risk, ENOV is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check ABT's competition here
ENOV vs ISRG Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, ISRG has a market cap of 143.8B. Regarding current trading prices, ENOV is priced at $22.02, while ISRG trades at $405.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas ISRG's P/E ratio is 42.20. In terms of profitability, ENOV's ROE is -0.60%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, ENOV is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check ISRG's competition here
ENOV vs SYK Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, SYK has a market cap of 126.6B. Regarding current trading prices, ENOV is priced at $22.02, while SYK trades at $330.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas SYK's P/E ratio is 24.66. In terms of profitability, ENOV's ROE is -0.60%, compared to SYK's ROE of +0.15%. Regarding short-term risk, ENOV is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check SYK's competition here
ENOV vs MDT Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, MDT has a market cap of 103.6B. Regarding current trading prices, ENOV is priced at $22.02, while MDT trades at $80.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas MDT's P/E ratio is 14.63. In terms of profitability, ENOV's ROE is -0.60%, compared to MDT's ROE of +0.10%. Regarding short-term risk, ENOV is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check MDT's competition here
ENOV vs BSX Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, BSX has a market cap of 64.6B. Regarding current trading prices, ENOV is priced at $22.02, while BSX trades at $43.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas BSX's P/E ratio is 14.02. In terms of profitability, ENOV's ROE is -0.60%, compared to BSX's ROE of +0.15%. Regarding short-term risk, ENOV is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check BSX's competition here
ENOV vs EW Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, EW has a market cap of 52.5B. Regarding current trading prices, ENOV is priced at $22.02, while EW trades at $91.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas EW's P/E ratio is 33.77. In terms of profitability, ENOV's ROE is -0.60%, compared to EW's ROE of +0.11%. Regarding short-term risk, ENOV is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check EW's competition here
ENOV vs RMD Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, RMD has a market cap of 28.8B. Regarding current trading prices, ENOV is priced at $22.02, while RMD trades at $198.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas RMD's P/E ratio is 18.42. In terms of profitability, ENOV's ROE is -0.60%, compared to RMD's ROE of +0.24%. Regarding short-term risk, ENOV is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check RMD's competition here
ENOV vs DXCM Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, DXCM has a market cap of 27B. Regarding current trading prices, ENOV is priced at $22.02, while DXCM trades at $69.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas DXCM's P/E ratio is 30.03. In terms of profitability, ENOV's ROE is -0.60%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, ENOV is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check DXCM's competition here
ENOV vs ZBH Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, ZBH has a market cap of 17.6B. Regarding current trading prices, ENOV is priced at $22.02, while ZBH trades at $91.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas ZBH's P/E ratio is 10.75. In terms of profitability, ENOV's ROE is -0.60%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, ENOV is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check ZBH's competition here
ENOV vs ABMD Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ENOV is priced at $22.02, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ENOV's ROE is -0.60%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ENOV is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check ABMD's competition here
ENOV vs SNN Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, SNN has a market cap of 12.8B. Regarding current trading prices, ENOV is priced at $22.02, while SNN trades at $30.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas SNN's P/E ratio is 16.36. In terms of profitability, ENOV's ROE is -0.60%, compared to SNN's ROE of +0.12%. Regarding short-term risk, ENOV is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check SNN's competition here
ENOV vs SWAV Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ENOV is priced at $22.02, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ENOV's ROE is -0.60%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ENOV is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check SWAV's competition here
ENOV vs ALGN Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, ALGN has a market cap of 12.4B. Regarding current trading prices, ENOV is priced at $22.02, while ALGN trades at $173.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas ALGN's P/E ratio is 15.81. In terms of profitability, ENOV's ROE is -0.60%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, ENOV is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check ALGN's competition here
ENOV vs PEN Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, PEN has a market cap of 12.4B. Regarding current trading prices, ENOV is priced at $22.02, while PEN trades at $315.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas PEN's P/E ratio is 82.38. In terms of profitability, ENOV's ROE is -0.60%, compared to PEN's ROE of +0.12%. Regarding short-term risk, ENOV is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check PEN's competition here
ENOV vs GMED Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, GMED has a market cap of 11.3B. Regarding current trading prices, ENOV is priced at $22.02, while GMED trades at $83.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas GMED's P/E ratio is 18.90. In terms of profitability, ENOV's ROE is -0.60%, compared to GMED's ROE of +0.13%. Regarding short-term risk, ENOV is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check GMED's competition here
ENOV vs PODD Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, PODD has a market cap of 10.9B. Regarding current trading prices, ENOV is priced at $22.02, while PODD trades at $157.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas PODD's P/E ratio is 29.32. In terms of profitability, ENOV's ROE is -0.60%, compared to PODD's ROE of +0.21%. Regarding short-term risk, ENOV is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check PODD's competition here
ENOV vs MASI Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, ENOV is priced at $22.02, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas MASI's P/E ratio is 44.43. In terms of profitability, ENOV's ROE is -0.60%, compared to MASI's ROE of +0.09%. Regarding short-term risk, ENOV is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check MASI's competition here
ENOV vs BRKR Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, BRKR has a market cap of 9.1B. Regarding current trading prices, ENOV is priced at $22.02, while BRKR trades at $59.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas BRKR's P/E ratio is 32.81. In terms of profitability, ENOV's ROE is -0.60%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, ENOV is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check BRKR's competition here
ENOV vs BIO-B Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, BIO-B has a market cap of 8.8B. Regarding current trading prices, ENOV is priced at $22.02, while BIO-B trades at $320.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas BIO-B's P/E ratio is 95.07. In terms of profitability, ENOV's ROE is -0.60%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, ENOV is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check BIO-B's competition here
ENOV vs GKOS Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, GKOS has a market cap of 8.3B. Regarding current trading prices, ENOV is priced at $22.02, while GKOS trades at $142.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas GKOS's P/E ratio is -165.03. In terms of profitability, ENOV's ROE is -0.60%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, ENOV is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check GKOS's competition here
ENOV vs BIO Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, BIO has a market cap of 8B. Regarding current trading prices, ENOV is priced at $22.02, while BIO trades at $295.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas BIO's P/E ratio is 31.83. In terms of profitability, ENOV's ROE is -0.60%, compared to BIO's ROE of +0.02%. Regarding short-term risk, ENOV is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check BIO's competition here
ENOV vs NARI Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ENOV is priced at $22.02, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas NARI's P/E ratio is -59.24. In terms of profitability, ENOV's ROE is -0.60%, compared to NARI's ROE of -0.00%. Regarding short-term risk, ENOV is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check NARI's competition here
ENOV vs LIVN Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, LIVN has a market cap of 4.6B. Regarding current trading prices, ENOV is priced at $22.02, while LIVN trades at $83.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas LIVN's P/E ratio is 20.77. In terms of profitability, ENOV's ROE is -0.60%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, ENOV is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check LIVN's competition here
ENOV vs IRTC Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, IRTC has a market cap of 3.9B. Regarding current trading prices, ENOV is priced at $22.02, while IRTC trades at $118.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas IRTC's P/E ratio is -211.46. In terms of profitability, ENOV's ROE is -0.60%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, ENOV is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check IRTC's competition here
ENOV vs AXNX Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ENOV is priced at $22.02, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ENOV's ROE is -0.60%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ENOV is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check AXNX's competition here
ENOV vs ITGR Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, ITGR has a market cap of 3.1B. Regarding current trading prices, ENOV is priced at $22.02, while ITGR trades at $91.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas ITGR's P/E ratio is 14.48. In terms of profitability, ENOV's ROE is -0.60%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, ENOV is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check ITGR's competition here
ENOV vs ESTA Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, ESTA has a market cap of 2.6B. Regarding current trading prices, ENOV is priced at $22.02, while ESTA trades at $87.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas ESTA's P/E ratio is -60.71. In terms of profitability, ENOV's ROE is -0.60%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, ENOV is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check ESTA's competition here
ENOV vs AXGN Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, AXGN has a market cap of 2.4B. Regarding current trading prices, ENOV is priced at $22.02, while AXGN trades at $44.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas AXGN's P/E ratio is 117.68. In terms of profitability, ENOV's ROE is -0.60%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, ENOV is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check AXGN's competition here
ENOV vs BFLY Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, BFLY has a market cap of 2.3B. Regarding current trading prices, ENOV is priced at $22.02, while BFLY trades at $8.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas BFLY's P/E ratio is -37.15. In terms of profitability, ENOV's ROE is -0.60%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, ENOV is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check BFLY's competition here
ENOV vs TMDX Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, TMDX has a market cap of 2.3B. Regarding current trading prices, ENOV is priced at $22.02, while TMDX trades at $67.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas TMDX's P/E ratio is 27.47. In terms of profitability, ENOV's ROE is -0.60%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, ENOV is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check TMDX's competition here
ENOV vs NUVA Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ENOV is priced at $22.02, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ENOV's ROE is -0.60%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ENOV is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check NUVA's competition here
ENOV vs UFPT Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, UFPT has a market cap of 2B. Regarding current trading prices, ENOV is priced at $22.02, while UFPT trades at $263.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas UFPT's P/E ratio is 26.87. In terms of profitability, ENOV's ROE is -0.60%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, ENOV is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check UFPT's competition here
ENOV vs NVCR Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, ENOV is priced at $22.02, while NVCR trades at $15.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas NVCR's P/E ratio is -10.12. In terms of profitability, ENOV's ROE is -0.60%, compared to NVCR's ROE of -0.51%. Regarding short-term risk, ENOV is more volatile compared to NVCR. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check NVCR's competition here
ENOV vs ATEC Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, ENOV is priced at $22.02, while ATEC trades at $9.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas ATEC's P/E ratio is -86.36. In terms of profitability, ENOV's ROE is -0.60%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, ENOV is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check ATEC's competition here
ENOV vs IART Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, IART has a market cap of 1.5B. Regarding current trading prices, ENOV is priced at $22.02, while IART trades at $18.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas IART's P/E ratio is 7.94. In terms of profitability, ENOV's ROE is -0.60%, compared to IART's ROE of -0.48%. Regarding short-term risk, ENOV is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check IART's competition here
ENOV vs AHCO Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, AHCO has a market cap of 1.4B. Regarding current trading prices, ENOV is priced at $22.02, while AHCO trades at $10.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas AHCO's P/E ratio is 23.20. In terms of profitability, ENOV's ROE is -0.60%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, ENOV is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check AHCO's competition here
ENOV vs HSKA Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ENOV is priced at $22.02, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ENOV's ROE is -0.60%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ENOV is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check HSKA's competition here
ENOV vs INSP Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, INSP has a market cap of 1.3B. Regarding current trading prices, ENOV is priced at $22.02, while INSP trades at $44.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas INSP's P/E ratio is 17.42. In terms of profitability, ENOV's ROE is -0.60%, compared to INSP's ROE of +0.18%. Regarding short-term risk, ENOV and INSP have similar daily volatility (3.82).Check INSP's competition here
ENOV vs PRCT Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, PRCT has a market cap of 1.3B. Regarding current trading prices, ENOV is priced at $22.02, while PRCT trades at $22.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas PRCT's P/E ratio is -12.41. In terms of profitability, ENOV's ROE is -0.60%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, ENOV is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check PRCT's competition here
ENOV vs IRMD Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, ENOV is priced at $22.02, while IRMD trades at $94.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas IRMD's P/E ratio is 47.27. In terms of profitability, ENOV's ROE is -0.60%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, ENOV is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check IRMD's competition here
ENOV vs AVNS Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, ENOV is priced at $22.02, while AVNS trades at $24.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas AVNS's P/E ratio is 27.69. In terms of profitability, ENOV's ROE is -0.60%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, ENOV is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check AVNS's competition here
ENOV vs SILK Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ENOV is priced at $22.02, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas SILK's P/E ratio is -18.96. In terms of profitability, ENOV's ROE is -0.60%, compared to SILK's ROE of -0.35%. Regarding short-term risk, ENOV is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check SILK's competition here
ENOV vs LMRI Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, ENOV is priced at $22.02, while LMRI trades at $11.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas LMRI's P/E ratio is -22.34. In terms of profitability, ENOV's ROE is -0.60%, compared to LMRI's ROE of -0.14%. Regarding short-term risk, ENOV is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check LMRI's competition here
ENOV vs FNA Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ENOV is priced at $22.02, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas FNA's P/E ratio is -19.83. In terms of profitability, ENOV's ROE is -0.60%, compared to FNA's ROE of -0.35%. Regarding short-term risk, ENOV is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check FNA's competition here
ENOV vs AORT Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, ENOV is priced at $22.02, while AORT trades at $22.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas AORT's P/E ratio is 34.41. In terms of profitability, ENOV's ROE is -0.60%, compared to AORT's ROE of +0.03%. Regarding short-term risk, ENOV is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check AORT's competition here
ENOV vs TNDM Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, ENOV is priced at $22.02, while TNDM trades at $15.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas TNDM's P/E ratio is -14.39. In terms of profitability, ENOV's ROE is -0.60%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, ENOV is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check TNDM's competition here
ENOV vs CNMD Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, CNMD has a market cap of 1B. Regarding current trading prices, ENOV is priced at $22.02, while CNMD trades at $34.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas CNMD's P/E ratio is 7.56. In terms of profitability, ENOV's ROE is -0.60%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, ENOV is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check CNMD's competition here
ENOV vs INMD Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, INMD has a market cap of 847.3M. Regarding current trading prices, ENOV is priced at $22.02, while INMD trades at $14.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas INMD's P/E ratio is 9.45. In terms of profitability, ENOV's ROE is -0.60%, compared to INMD's ROE of +0.13%. Regarding short-term risk, ENOV is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check INMD's competition here
ENOV vs CSII Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ENOV is priced at $22.02, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas CSII's P/E ratio is -20.83. In terms of profitability, ENOV's ROE is -0.60%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ENOV is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check CSII's competition here
ENOV vs CBLL Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, CBLL has a market cap of 757.3M. Regarding current trading prices, ENOV is priced at $22.02, while CBLL trades at $19.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas CBLL's P/E ratio is -12.25. In terms of profitability, ENOV's ROE is -0.60%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, ENOV is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check CBLL's competition here
ENOV vs SIBN Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, SIBN has a market cap of 748.6M. Regarding current trading prices, ENOV is priced at $22.02, while SIBN trades at $16.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas SIBN's P/E ratio is -43.28. In terms of profitability, ENOV's ROE is -0.60%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, ENOV is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check SIBN's competition here
ENOV vs CRY Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, ENOV is priced at $22.02, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas CRY's P/E ratio is 425.71. In terms of profitability, ENOV's ROE is -0.60%, compared to CRY's ROE of +0.03%. Regarding short-term risk, ENOV is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check CRY's competition here
ENOV vs SSII Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, SSII has a market cap of 704.5M. Regarding current trading prices, ENOV is priced at $22.02, while SSII trades at $3.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas SSII's P/E ratio is -68.66. In terms of profitability, ENOV's ROE is -0.60%, compared to SSII's ROE of -0.23%. Regarding short-term risk, ENOV is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check SSII's competition here
ENOV vs TCMD Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, TCMD has a market cap of 682.8M. Regarding current trading prices, ENOV is priced at $22.02, while TCMD trades at $30.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas TCMD's P/E ratio is 34.40. In terms of profitability, ENOV's ROE is -0.60%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, ENOV is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check TCMD's competition here
ENOV vs BVS Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, BVS has a market cap of 662.6M. Regarding current trading prices, ENOV is priced at $22.02, while BVS trades at $9.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas BVS's P/E ratio is 13.04. In terms of profitability, ENOV's ROE is -0.60%, compared to BVS's ROE of +0.16%. Regarding short-term risk, ENOV is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check BVS's competition here
ENOV vs SRDX Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, ENOV is priced at $22.02, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas SRDX's P/E ratio is -34.66. In terms of profitability, ENOV's ROE is -0.60%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, ENOV is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check SRDX's competition here
ENOV vs CERS Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, CERS has a market cap of 599.1M. Regarding current trading prices, ENOV is priced at $22.02, while CERS trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas CERS's P/E ratio is -59.68. In terms of profitability, ENOV's ROE is -0.60%, compared to CERS's ROE of -0.15%. Regarding short-term risk, ENOV is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check CERS's competition here
ENOV vs BWAY Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, BWAY has a market cap of 595M. Regarding current trading prices, ENOV is priced at $22.02, while BWAY trades at $15.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas BWAY's P/E ratio is 38.54. In terms of profitability, ENOV's ROE is -0.60%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, ENOV is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check BWAY's competition here
ENOV vs CLPT Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, CLPT has a market cap of 582.7M. Regarding current trading prices, ENOV is priced at $22.02, while CLPT trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas CLPT's P/E ratio is -19.24. In terms of profitability, ENOV's ROE is -0.60%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, ENOV is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check CLPT's competition here
ENOV vs APEN Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ENOV is priced at $22.02, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas APEN's P/E ratio is -9.43. In terms of profitability, ENOV's ROE is -0.60%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ENOV is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check APEN's competition here
ENOV vs NPCE Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, NPCE has a market cap of 563.6M. Regarding current trading prices, ENOV is priced at $22.02, while NPCE trades at $16.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas NPCE's P/E ratio is -28.50. In terms of profitability, ENOV's ROE is -0.60%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, ENOV is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check NPCE's competition here
ENOV vs CTKB Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, CTKB has a market cap of 560.5M. Regarding current trading prices, ENOV is priced at $22.02, while CTKB trades at $4.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas CTKB's P/E ratio is -33.38. In terms of profitability, ENOV's ROE is -0.60%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, ENOV is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check CTKB's competition here
ENOV vs PACB Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, PACB has a market cap of 537.3M. Regarding current trading prices, ENOV is priced at $22.02, while PACB trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas PACB's P/E ratio is -3.53. In terms of profitability, ENOV's ROE is -0.60%, compared to PACB's ROE of -4.88%. Regarding short-term risk, ENOV is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check PACB's competition here
ENOV vs ZIMV Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, ENOV is priced at $22.02, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, ENOV's ROE is -0.60%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, ENOV is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check ZIMV's competition here
ENOV vs KIDS Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, KIDS has a market cap of 515.8M. Regarding current trading prices, ENOV is priced at $22.02, while KIDS trades at $20.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas KIDS's P/E ratio is -19.50. In terms of profitability, ENOV's ROE is -0.60%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, ENOV is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check KIDS's competition here
ENOV vs DCTH Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, DCTH has a market cap of 447.1M. Regarding current trading prices, ENOV is priced at $22.02, while DCTH trades at $12.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas DCTH's P/E ratio is 1295.00. In terms of profitability, ENOV's ROE is -0.60%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, ENOV is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check DCTH's competition here
ENOV vs VREX Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, VREX has a market cap of 420.2M. Regarding current trading prices, ENOV is priced at $22.02, while VREX trades at $9.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas VREX's P/E ratio is 10.51. In terms of profitability, ENOV's ROE is -0.60%, compared to VREX's ROE of -0.18%. Regarding short-term risk, ENOV is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check VREX's competition here
ENOV vs OFIX Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, OFIX has a market cap of 391.3M. Regarding current trading prices, ENOV is priced at $22.02, while OFIX trades at $9.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas OFIX's P/E ratio is -39.43. In terms of profitability, ENOV's ROE is -0.60%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, ENOV is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check OFIX's competition here
ENOV vs AVR Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, AVR has a market cap of 359.8M. Regarding current trading prices, ENOV is priced at $22.02, while AVR trades at $9.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas AVR's P/E ratio is -4.39. In terms of profitability, ENOV's ROE is -0.60%, compared to AVR's ROE of -1.24%. Regarding short-term risk, ENOV is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check AVR's competition here
ENOV vs ELMD Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, ELMD has a market cap of 350.8M. Regarding current trading prices, ENOV is priced at $22.02, while ELMD trades at $42.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas ELMD's P/E ratio is 36.21. In terms of profitability, ENOV's ROE is -0.60%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, ENOV is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check ELMD's competition here
ENOV vs SGHT Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, SGHT has a market cap of 317.8M. Regarding current trading prices, ENOV is priced at $22.02, while SGHT trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas SGHT's P/E ratio is -9.27. In terms of profitability, ENOV's ROE is -0.60%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, ENOV is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check SGHT's competition here
ENOV vs SMLR Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, ENOV is priced at $22.02, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas SMLR's P/E ratio is 3.92. In terms of profitability, ENOV's ROE is -0.60%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, ENOV is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check SMLR's competition here
ENOV vs TMCI Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, TMCI has a market cap of 277M. Regarding current trading prices, ENOV is priced at $22.02, while TMCI trades at $4.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas TMCI's P/E ratio is -4.54. In terms of profitability, ENOV's ROE is -0.60%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, ENOV is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check TMCI's competition here
ENOV vs CATX Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, CATX has a market cap of 274.2M. Regarding current trading prices, ENOV is priced at $22.02, while CATX trades at $3.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas CATX's P/E ratio is -2.52. In terms of profitability, ENOV's ROE is -0.60%, compared to CATX's ROE of -0.42%. Regarding short-term risk, ENOV is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check CATX's competition here
ENOV vs SENS Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, SENS has a market cap of 248.3M. Regarding current trading prices, ENOV is priced at $22.02, while SENS trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas SENS's P/E ratio is -2.97. In terms of profitability, ENOV's ROE is -0.60%, compared to SENS's ROE of -1.30%. Regarding short-term risk, ENOV is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check SENS's competition here
ENOV vs PMI Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, PMI has a market cap of 246.8M. Regarding current trading prices, ENOV is priced at $22.02, while PMI trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas PMI's P/E ratio is -0.13. In terms of profitability, ENOV's ROE is -0.60%, compared to PMI's ROE of +4.99%. Regarding short-term risk, ENOV is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check PMI's competition here
ENOV vs MGRM Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, ENOV is priced at $22.02, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas MGRM's P/E ratio is -12.00. In terms of profitability, ENOV's ROE is -0.60%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, ENOV is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check MGRM's competition here
ENOV vs NVRO Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ENOV is priced at $22.02, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ENOV's ROE is -0.60%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ENOV is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check NVRO's competition here
ENOV vs QTRX Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, QTRX has a market cap of 213.9M. Regarding current trading prices, ENOV is priced at $22.02, while QTRX trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas QTRX's P/E ratio is -2.84. In terms of profitability, ENOV's ROE is -0.60%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, ENOV is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check QTRX's competition here
ENOV vs RXST Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, RXST has a market cap of 211.1M. Regarding current trading prices, ENOV is priced at $22.02, while RXST trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas RXST's P/E ratio is -7.08. In terms of profitability, ENOV's ROE is -0.60%, compared to RXST's ROE of -0.17%. Regarding short-term risk, ENOV is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check RXST's competition here
ENOV vs EYES Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, ENOV is priced at $22.02, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas EYES's P/E ratio is N/A. In terms of profitability, ENOV's ROE is -0.60%, compared to EYES's ROE of -2.64%. Regarding short-term risk, ENOV is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check EYES's competition here
ENOV vs ANIK Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, ANIK has a market cap of 199.7M. Regarding current trading prices, ENOV is priced at $22.02, while ANIK trades at $15.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas ANIK's P/E ratio is 30.63. In terms of profitability, ENOV's ROE is -0.60%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, ENOV is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check ANIK's competition here
ENOV vs PROF Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, PROF has a market cap of 199.4M. Regarding current trading prices, ENOV is priced at $22.02, while PROF trades at $6.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas PROF's P/E ratio is -5.31. In terms of profitability, ENOV's ROE is -0.60%, compared to PROF's ROE of -0.70%. Regarding short-term risk, ENOV is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check PROF's competition here
ENOV vs FOCL Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, FOCL has a market cap of 192.8M. Regarding current trading prices, ENOV is priced at $22.02, while FOCL trades at $5.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas FOCL's P/E ratio is -10.40. In terms of profitability, ENOV's ROE is -0.60%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, ENOV is more volatile compared to FOCL. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check FOCL's competition here
ENOV vs BSGM Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, ENOV is priced at $22.02, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas BSGM's P/E ratio is -5.81. In terms of profitability, ENOV's ROE is -0.60%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, ENOV is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check BSGM's competition here
ENOV vs INGN Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, INGN has a market cap of 187.6M. Regarding current trading prices, ENOV is priced at $22.02, while INGN trades at $6.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas INGN's P/E ratio is -7.62. In terms of profitability, ENOV's ROE is -0.60%, compared to INGN's ROE of -0.13%. Regarding short-term risk, ENOV is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check INGN's competition here
ENOV vs TLSI Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, TLSI has a market cap of 179.7M. Regarding current trading prices, ENOV is priced at $22.02, while TLSI trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas TLSI's P/E ratio is -2.82. In terms of profitability, ENOV's ROE is -0.60%, compared to TLSI's ROE of +1.63%. Regarding short-term risk, ENOV is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check TLSI's competition here
ENOV vs MDGS Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, ENOV is priced at $22.02, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ENOV's ROE is -0.60%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ENOV is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check MDGS's competition here
ENOV vs QIPT Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, ENOV is priced at $22.02, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas QIPT's P/E ratio is -15.87. In terms of profitability, ENOV's ROE is -0.60%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, ENOV is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check QIPT's competition here
ENOV vs CVRX Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, CVRX has a market cap of 157.6M. Regarding current trading prices, ENOV is priced at $22.02, while CVRX trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas CVRX's P/E ratio is -2.94. In terms of profitability, ENOV's ROE is -0.60%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, ENOV is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check CVRX's competition here
ENOV vs QTI Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, QTI has a market cap of 109.6M. Regarding current trading prices, ENOV is priced at $22.02, while QTI trades at $4.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas QTI's P/E ratio is -5.94. In terms of profitability, ENOV's ROE is -0.60%, compared to QTI's ROE of -63.31%. Regarding short-term risk, ENOV is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check QTI's competition here
ENOV vs LUCD Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, LUCD has a market cap of 107.4M. Regarding current trading prices, ENOV is priced at $22.02, while LUCD trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas LUCD's P/E ratio is -2.84. In terms of profitability, ENOV's ROE is -0.60%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, ENOV is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check LUCD's competition here
ENOV vs ICAD Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, ENOV is priced at $22.02, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas ICAD's P/E ratio is -20.37. In terms of profitability, ENOV's ROE is -0.60%, compared to ICAD's ROE of -0.06%. Regarding short-term risk, ENOV is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check ICAD's competition here
ENOV vs RCEL Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, RCEL has a market cap of 105.6M. Regarding current trading prices, ENOV is priced at $22.02, while RCEL trades at $4.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas RCEL's P/E ratio is -2.71. In terms of profitability, ENOV's ROE is -0.60%, compared to RCEL's ROE of +3.05%. Regarding short-term risk, ENOV is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check RCEL's competition here
ENOV vs OWLT Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, OWLT has a market cap of 103.9M. Regarding current trading prices, ENOV is priced at $22.02, while OWLT trades at $5.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas OWLT's P/E ratio is -41.00. In terms of profitability, ENOV's ROE is -0.60%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, ENOV is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check OWLT's competition here
ENOV vs HSDT Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, HSDT has a market cap of 102.8M. Regarding current trading prices, ENOV is priced at $22.02, while HSDT trades at $1.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas HSDT's P/E ratio is -0.02. In terms of profitability, ENOV's ROE is -0.60%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, ENOV is less volatile compared to HSDT. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check HSDT's competition here
ENOV vs HJLI Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, ENOV is priced at $22.02, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas HJLI's P/E ratio is N/A. In terms of profitability, ENOV's ROE is -0.60%, compared to HJLI's ROE of -0.66%. Regarding short-term risk, ENOV is less volatile compared to HJLI. This indicates potentially lower risk in terms of short-term price fluctuations for ENOV.Check HJLI's competition here
ENOV vs ASXC Comparison July 2026
ENOV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ENOV stands at 1.3B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, ENOV is priced at $22.02, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ENOV currently has a P/E ratio of 6.51, whereas ASXC's P/E ratio is -1.12. In terms of profitability, ENOV's ROE is -0.60%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, ENOV is more volatile compared to ASXC. This indicates potentially higher risk in terms of short-term price fluctuations for ENOV.Check ASXC's competition here